Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Lessened by ARK Investment Management LLC

ARK Investment Management LLC reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 8.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,933,851 shares of the biotechnology company’s stock after selling 167,187 shares during the quarter. ARK Investment Management LLC owned approximately 7.14% of Arcturus Therapeutics worth $32,817,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after buying an additional 846 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after buying an additional 3,705 shares during the last quarter. Spire Wealth Management lifted its position in shares of Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Arcturus Therapeutics by 954.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after buying an additional 14,330 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. BTIG Research assumed coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, February 14th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average price target of $65.00.

Arcturus Therapeutics Trading Down 3.8 %

Arcturus Therapeutics stock opened at $16.06 on Wednesday. The stock has a market cap of $435.07 million, a price-to-earnings ratio of -7.23 and a beta of 2.62. The company’s 50-day moving average price is $16.98 and its two-hundred day moving average price is $18.81. Arcturus Therapeutics Holdings Inc. has a 52 week low of $14.30 and a 52 week high of $45.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.